Literature DB >> 16580177

Opposing effects of beta-arrestin1 and beta-arrestin2 on activation and degradation of Src induced by protease-activated receptor 1.

Fang-Ting Kuo1, Te-Ling Lu, Hua-Wen Fu.   

Abstract

Protease-activated receptor 1 (PAR1), a G protein-coupled receptor for thrombin, is irreversibly proteolytically activated. beta-Arrestin1 and beta-arrestin2 have been reported to have different effects on signal desensitization and transduction of PAR1. In this study, we investigated whether beta-arrestin1 and beta-arrestin2 regulate Src-dependent activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) induced by PAR1 in HEK 293 cells. Our results show that PAR1-mediated activation of Src and ERK1/2 in HEK 293 cells was increased with overexpression of beta-arrestin1 or depletion of beta-arrestin2. PAR1-mediated activation of Src and ERK1/2 in HEK 293 cells was decreased or eliminated with depletion of beta-arrestin1 or overexpression of beta-arrestin2. Furthermore, depletion of beta-arrestin2 blocked PAR1-induced degradation of Src. Thus, beta-arrestin1 and beta-arrestin2 have opposing roles in regulating the activation of Src induced by PAR1. beta-Arrestin2 also appears to promote PAR1-induced degradation of Src. This degradation of Src provides a possible mechanism for terminating PAR1 signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580177     DOI: 10.1016/j.cellsig.2006.02.009

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  11 in total

Review 1.  Regulation of inflammation by β-arrestins: Not just receptor tales.

Authors:  Neil J Freedman; Sudha K Shenoy
Journal:  Cell Signal       Date:  2017-02-09       Impact factor: 4.315

2.  β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation.

Authors:  Georgios Kallifatidis; Daniel Munoz; Rajendra Kumar Singh; Nicole Salazar; James J Hoy; Bal L Lokeshwar
Journal:  Mol Cancer Res       Date:  2016-02-26       Impact factor: 5.852

3.  Constitutive coupling of a naturally occurring human alpha1a-adrenergic receptor genetic variant to EGFR transactivation pathway.

Authors:  Anush Oganesian; Vladimir Yarov-Yarovoy; William C Parks; Debra A Schwinn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-16       Impact factor: 11.205

4.  beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations.

Authors:  S J Sanni; J T Hansen; M M Bonde; T Speerschneider; G L Christensen; S Munk; S Gammeltoft; J L Hansen
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  GPR54 regulates ERK1/2 activity and hypothalamic gene expression in a Gα(q/11) and β-arrestin-dependent manner.

Authors:  Jacob M Szereszewski; Macarena Pampillo; Maryse R Ahow; Stefan Offermanns; Moshmi Bhattacharya; Andy V Babwah
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

6.  Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptors.

Authors:  Robert H Oakley; Javier Revollo; John A Cidlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

7.  β-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation.

Authors:  Alisa Boutin; Elena Eliseeva; Marvin C Gershengorn; Susanne Neumann
Journal:  FASEB J       Date:  2014-04-10       Impact factor: 5.191

Review 8.  Beta-arrestin-mediated signaling in the heart.

Authors:  Priyesh A Patel; Douglas G Tilley; Howard A Rockman
Journal:  Circ J       Date:  2008-10-07       Impact factor: 2.993

9.  Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling.

Authors:  John M Busillo; Sylvain Armando; Rajarshi Sengupta; Olimpia Meucci; Michel Bouvier; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

Review 10.  Beta-Arrestins in the Treatment of Heart Failure Related to Hypertension: A Comprehensive Review.

Authors:  Ahmed Rakib; Taslima Akter Eva; Saad Ahmed Sami; Saikat Mitra; Iqbal Hossain Nafiz; Ayan Das; Abu Montakim Tareq; Firzan Nainu; Kuldeep Dhama; Talha Bin Emran; Jesus Simal-Gandara
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.